Loading
A phase 1/2 trial of HDM2017 and fruquintinib in colorectal cancer, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., not yet recruiting.
A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer is a phase 1/2, interventional study registered as NCT07621159 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2026-07-15 and due to reach its primary completion in 2027-11-01. Interventions recorded: HDM2017; Fruquintinib. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Maximum Tolerated Dose (MTD); Recommended Phase 2 Dose (RP2D); Type, incidence and severity of Adverse Events. Colorectal eligibility wording from the registry: "Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.